Harmony Biosciences (HRMY) Tops Q2 EPS by 20c ; Offers Guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $200.5 million versus the consensus estimate of $204.59 million.

GUIDANCE:

Harmony Biosciences sees FY2025 revenue of $820-860 million, versus the consensus of $843.6 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• AMN Healthcare (AMN) Reiterated at Market Outperform by Citizens
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits